Rocket Pharmaceuticals Files 8-K
Ticker: RCKT · Form: 8-K · Filed: Mar 27, 2026 · CIK: 0001281895
| Field | Detail |
|---|---|
| Company | Rocket Pharmaceuticals, Inc. (RCKT) |
| Form Type | 8-K |
| Filed Date | Mar 27, 2026 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, filing
TL;DR
Rocket Pharma dropped an 8-K, check the exhibits for news.
AI Summary
Rocket Pharmaceuticals, Inc. filed an 8-K on March 27, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). The filing includes an iXBRL 8-K document and exhibits such as EX-99.1 and graphic files, along with XBRL data files.
Why It Matters
This filing indicates Rocket Pharmaceuticals is providing updated information or disclosures to the public, which could contain material updates relevant to investors.
Risk Assessment
Risk Level: low — This is a routine filing for an 8-K, typically containing disclosures or exhibit updates, without immediate indication of significant negative events.
Key Players & Entities
- ROCKET PHARMACEUTICALS, INC. (company) — Filer
- 0001281895 (company) — CIK
- 2026-03-27 (date) — Filing Date
- 2026-03-26 (date) — Period of Report
FAQ
What specific information is disclosed under Item 7.01 (Regulation FD Disclosure)?
The filing itself does not detail the specific content of the Regulation FD Disclosure; it only indicates that this item is being reported.
What types of exhibits are included in this 8-K filing?
The filing includes an iXBRL 8-K document, EX-99.1, graphic files (image00001.jpg), and various XBRL data files including schema, label, presentation, and instance documents.
What is the CIK number for Rocket Pharmaceuticals, Inc.?
The CIK number for Rocket Pharmaceuticals, Inc. is 0001281895.
When was this 8-K filing accepted by the SEC?
This 8-K filing was accepted by the SEC on March 27, 2026, at 07:32:50.
What is the business address and contact number for Rocket Pharmaceuticals, Inc.?
The business address is 350 FIFTH AVENUE SUITE 7530 NEW YORK NY 10118, and the contact number is 646-440-9100.
Filing Stats: 605 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2026-03-27 07:32:50
Key Financial Figures
- $0.01 — nge on which registered Common stock, $0.01 par value RCKT The Nasdaq Global Ma
Filing Documents
- ef20069038_8k.htm (8-K) — 30KB
- ef20069038_ex99-1.htm (EX-99.1) — 31KB
- image00001.jpg (GRAPHIC) — 4KB
- 0001140361-26-011573.txt ( ) — 200KB
- rckt-20260326.xsd (EX-101.SCH) — 4KB
- rckt-20260326_lab.xml (EX-101.LAB) — 21KB
- rckt-20260326_pre.xml (EX-101.PRE) — 16KB
- ef20069038_8k_htm.xml (XML) — 4KB
01
Item 7.01. Regulation FD Disclosure. On March 27, 2026, Rocket Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration (FDA) has approved KRESLADI (marnetegragene autotemcel), an autologous hematopoietic stem cell-based gene therapy indicated for the treatment of pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I) due to biallelic variants in ITGB2 without an available human leukocyte antigen-matched sibling donor for allogeneic hematopoietic stem cell transplant. With the approval of KRESLADI, the FDA granted the Company a Rare Pediatric Disease Priority Review Voucher (PRV), a program designed to encourage development of therapies for rare pediatric diseases. The Company intends to evaluate strategic options to monetize the PRV in a manner designed to enhance financial flexibility and maximize shareholder value. A copy of the press release is included as Exhibit 99.1 hereto and is incorporated herein by reference. The information under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the "Exchange Act") or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. 99.1 Press Release of Rocket Pharmaceuticals, Inc. dated March 27, 2026. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Rocket Pharmaceuticals, Inc. Date: March 27, 2026 By: /s/ Martin Wilson Martin Wilson General Counsel and Chief Corporate Officer